[Present status of periodontal regeneration - FGF-2 and Teriparatide - ].
Periodontal regenerative therapy is required to regain the tooth function and oral health for patients with periodontal diseases. We reported that topical application of basic fibroblast growth factor (FGF-2) into alveolar bone defects stimulated significant periodontal regeneration in periodontitis patients. On the other hand, subcutaneous administration of Teriparatide, a drug composed of the first 34 amino acids of parathyroid hormone that has anabolic effects for osteoporosis, has been reported to induce periodontal regeneration in the clinical trial. Both of the therapies have been expected to be the periodontal regeneration therapy of the next generation. In this review, we introduce the present status of these new periodontal regenerative therapies.
Department of Periodontology, Osaka University Graduate School of Dentistry, Japan.
Masahide
M
Takedachi
Shinya
S
Murakami
D000287:Administration, Topical; D016301:Alveolar Bone Loss / Q000188:drug therapy*; D000818:Animals; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D006801:Humans; D007279:Injections, Subcutaneous; D044968:Regenerative Medicine / Q000379:methods* / Q000639:trends; D019379:Teriparatide / Q000008:administration & dosage*
D050071:Bone Density Conservation Agents; D016222:Fibroblast Growth Factor 2; D019379:Teriparatide